NTNikolay N. Tsyba

Nikolay N. Tsyba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikolay N. Tsyba has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation of hematological day hospitals in the federal districts and regions of the Russian Federation

    by O. V. Lazareva, E. S. Maloletkina, N. N. Tsyba, O. A. Shuhov, Yu. A. Chabaeva, V. V. Troitskaya, E. N. Parovichnikova

    Introduction . Over the period from 2019 to 2023, there has been an increase in the prevalence of hematological diseases (malignant and non- malignant) (HemD). This situation once again highlights the need to ensure the availability of accessible specialized medical care (SMC) and its continuity at all stages, which is possible in a hematological day hospital (HDH). Aim: To assess the availability of HDH in the public healthcare sector of the Russian Federation (RF), its Federal Districts (FD), and constituent entities. Materials and methods . Information from the reporting industry forms of federal statistical observation No. 14-DS (FFSN No. 14-DS) for 2019–2023 and data from territorial compulsory health insurance funds for 85 constituent entities of the Russian Federation were analyzed. Results. By 2023, hematological services were organized in 85 of the 89 constituent entities of the RF, while HDH were only available in 63 (74%). HDH operate both in 24-hour hospitals (CH) and in outpatient settings. The number of hematological beds for adults increased by 21.7% from 2019 to 2023, from 533 to 636 beds. From 2019 to 2023, the provision of adult population with HDH in the Russian Federation increased by 28% from 0.046 to 0.059 per 10,000 adults respectively. A positive trend in the analyzed indicators was observed in all federal districts, with the exception of the Far Eastern federal district, where there was a sharp decrease in the provision of HDH from 0.06 to 0.03 due to a change in a change in bed profile to oncology. The average increase in the number of hospitalizations in the HDH per 10,000 adult populations between 2019 and 2023 was 332% (from 2.9 to 12.53). The average duration of treatment in the HDH in 2019 and 2023 in the Russian Federation decreased by 16%, from 6.9 to 5.8 days, respectively. In 2023 SMC in HDH was provided in 55,930 cases in the Russian Federation, of which 26,117 (47%) were at the outpatient stage. To support HDH operations, physicians from previously established hematology departments were involved. For the financial support of HDH, the formulation of the clinical-statistical group ds19.033 “Hospitalization for diagnostic purposes with molecular genetic and/or immunohistochemical testing or immunophenotyping” in the State Guarantees Program was amended, enabling high-tech diagnostics of hematological diseases. Conclusion. HDH are insufficiently integrated into the healthcare system of the RF and are absent in 22 regions. In the constituent entities of the RF, it is necessary to continue organizing HDH, which are an economically viable form of providing emergency medical care to the adult population, allowing for the effective examination and treatment of hematological patients while maintaining their usual quality of life. Acknowledgment. The authors express their gratitude to the heads of the hematology service in the regions of the RF, as well as to the staff of the FSBI Russian Research Institute of Health of the Ministry of Health of the RF for the materials provided and for their assistance in selecting information materials.


  • Open Access

    Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety

    by N. N. Tsyba, A. G. Turkina

    The prognosis of chronic myeloid leukemia (CML) has changed during the past two decades from a disease with an overall survival of 5 years only to one in which patients can enjoy a near normal life-expectancy. Such remarkable improvement in the patients’ outcome is mainly due to the introduction of imatinib into the clinic (the first approved tyrosine kinase inhibitor [TKI]), but also to the approvals of others TKIs. Currently, there are six TKIs available for CML treatment in clinical practice. The article discusses the effectiveness and safety of only the 2nd generation of ITCs, each of which has its own range of both adverse events and advantages when prescribed in the first or subsequent lines of CML therapy. Although a proportion of patients (around 25%) will be able to successfully discontinue TKI treatment after achieving a deep molecular remission, most of them will require to keep on treatment indefinitely. In such a situation, it is crucial for doctors caring for CML patients to be aware of which TKIs are available for each particular clinical situation, what can be expected from them, and how to manage their potential side effects. In the present review, we will briefly address these issues from a practical point of view.

  • Open Access

    25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions

    by N. N. Tsyba, A. G. Turkina

    More than 25 years ago, the discovery of imatinib, the first ATP-competitive inhibitor of BCR::ABL1, the driving oncoprotein of chronic myeloid leukemia, revolutionized patients life by transforming a fatal condition into a chronic disease. The review analyzes data on the effectiveness of chronic myeloid leukemia therapy with tyrosine kinase inhibitors and a number of provisions that require discussion and, possibly, revision at the present stage. The first clinical trials of imatinib, the first ATP- competitive inhibitor of BCR::ABL1, started in 1998, demonstrated extremely high therapeutic efficacy, impressively increasing the rates of relapse-free and overall survival in patients with chronic myeloid leukemia. The life expectancy of the overwhelming number of patients has become comparable to the life expectancy of the main population. Over the years, the arsenal of therapeutic agents for the treatment of chronic myeloid leukemia has been significantly enriched: three ATP-competitive tyrosine kinase inhibitors of the 2nd generation have been created and approved for use, 2 drugs of the 3rd generation: ponatinib, and the first allosteric tyrosine kinase inhibitor asciminib have been registered for the treatment of patients with the T315I mutation. Regular cytogenetic and molecular genetic monitoring makes it possible to adequately assess the volume of the leukemic clone and is an integral part of evaluating the effectiveness of therapy, allowing to control and maintain remission in a number of patients without the use of tyrosine kinase inhibitors. Today imatinib remains the key drug of the 1st line of therapy, at the same time, the appointment of 2nd generation tyrosine kinase inhibitors in the first line of therapy can lead to an earlier and deeper response. The choice of the drug for each individual patient, taking into account the best tolerability and maximum effectiveness, allows individualizing treatment and expanding the possibilities of therapy.

  • Open Access

    Staffing of the hematology service of the Russian Federation

    by O. V. Lazareva, E. S. Maloletkina, H. L. Julhakyan, D. A. Shvets, N. N. Tsyba, E. N. Parovichnikova, У. Л. Джулакян

    Introduction. As part of the implementation of the federal project Development of a network of national medical research centers and the introduction of innovative medical technologies, one of the activities of the National Medical Research Center for Hematology (Center) is the analysis of the staffi ng of medical organizations (MO) of the constituent entities of the Russian Federation (RF) by hematologists.Aim — to analyze the dynamics of staffi ng by hematologists of MO in the RF.Materials and methods. Data from the Federal State Statistics Service (Rosstat) — Federal Statistical Observation Form No. 30 “Information about a medical organization” of the constituent entities of the Russian Federation for 2012–2020, reference books of the Central Research Institute of Organization and Informatization Health of the Russian Ministry of Health in the Russian Federation, information obtained from the results of on-site events of the National Medical Research Center for Hematology, including expert assessments were used.Results. The hematological service is organized in all subjects of the RF, with the exception of the Chukotka and Nenets Autonomous Okrug, Republic of Kalmykia and Altai, as well as the Jewish Autonomous Region. As of December 31, 2021, 1,594 hematologists work in the constituent entities of the RF, of which 460 specialists are in outpatient care and 1133 specialists in hospital settings. Analysis of the availability of full-time positions of hematologists per 10,000 populations in the Russian Federation in dynamics for 2012–2020 revealed fl uctuations in the values of this indicator from 0.06 to 0.17. The largest “failure” in the provision of hematologists occurred in 2014 in almost all federal districts (FD) of the Russian Federation. Only the Urals FD maintains the stability of the indicator of availability of these specialists. Over the past 3 years, there has been an increase in the number of full-time positions of hematologists, while the staffi ng of individuals reduced due to the lack (increase) of new employees and slightly offset by an increase in the coeffi cient of internal part-time work. Thus, the highest combination coeffi cient was noted in 2020 in the Ural (1.49) and Siberian (1.45) FD, the lowest in the North-Western FD (1.09). In accordance with the legal act regulating the activities of the hematology service, the standard for calculating the positions of outpatient hematologists is 1 doctor per 200 thousand of the population, however, the provision of full-time positions for the outpatient stage of care remains not achieved (2021 — 0.92 per 200 thousand); at least 731 doctors are needed against the existing 456 specialists. The staffi ng standard of the department of hematology corresponds to one medical position per 10 beds. Compliance with regulations regarding the formation of the staffi ng table of the inpatient unit was noted in 95% of the constituent entities of the Russian Federation.Conclusion. The issues of personnel shortage of hematologists are relevant. The shortage of hematologists in the Russian Federation indicates the lack of attractiveness of remuneration and indicates the need for management decisions to be made by the Government of the Russian Federation and executive authorities of the constituent entities of the Russian Federation aimed at developing mechanisms for maintaining the human resource of hematologists in the healthcare system.


  • Open Access

    A long-term follow-up of observation in treatment-free remission in patients with chronic myeloid leukemia

    by A. N. Petrova, E. Yu. Chelysheva, I. S. Nemchenko, A. V. Bykova, M. A. Gurianova, Е. А. Кузьмина, N. N. Tsyba, A. V. Kokhno, A. G. Turkina

       Introduction. The option of observation without therapy with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients is already included in Russian and international clinical guidelines. Evaluation of long-term follow-up results of treatment free remission (TFR) in CML patients is relevant for the introduction of this approach into routine clinical practice.   Aim — to demonstrate the outcomes in a long-term follow-up of CML patients who discontinued TKI therapy in the RU-SKI trial.   Patients and methods. The prospective study included 98 CML patients with TKI therapy duration ≥ 3 years and a deep molecular response (DMR, BCR::ABL1 ≤ 0.01 %) duration ≥ 2 years. TKI therapy was resumed with the loss of a major MR (MMR, BCR::ABL1 > 0,1 %).   Results. Median time of follow-up after TKI discontinuation was 64 months (range of 51–86 months). Survival without MMR loss at 3 and 5 years after TKI discontinuation was 51 % (CI 41–61 %) and 46 % (CI 36–57 %) respectively. From 3 to 5 years of follow-up without therapy, the loss of MMR occurred in 2 (4 %) patients. There was no MMR loss observed after 5 years of follow-up. In patients with first and second treatment discontinuation, survival without MMR loss was 50 % versus 12,5 %(р = 0,039). All 50 patients with molecular relapses regained MMR and MR4 after TKI therapy resumption. BCR::ABL1 level fluctuations 0,01–0,1 % were in 62 % (n = 29) patients, who were in TFR at the time of analysis. Loss of MR4 was observed in 38 (42 %) from 90 patients with first TKI discontinuation. Survival without MMR loss from MO4 loss was 24 % at 5 years after TKI discontinuation. Loss of MO4 in the first 3 months after TKI cessation was associated with a high probability of further MMR loss (8 % versus 54 % in patients with loss of MO4 for > 3 months, p = 0.00015).   Conclusion. The low frequency of late relapses (4 % after 3 years of follow-up) and the possibility of long-term persistence of minimal residual disease (MRD) after discontinuation of therapy determine the need to optimize the timing of molecular monitoring, taking into account the MRD status of patients.


  • Open Access

    Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia

    by Ekaterina Yu. Chelysheva, Anna N. Petrova, Oleg A. Shukhov, Anastasiia V. Bykova, Irina S. Nemchenko, Margarita A. Gurianova, Nikolay N. Tsyba, Anna G. Turkina

    Background. Withdrawal syndrome (WS) a musculoskeletal pain after discontinuation of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML) has been described in the treatment-free remission (TFR) studies. The pathophysiological mechanisms and predisposing factors of WS have not been well established. Aim. Our aim was to evaluate clinical features and factors associated with WS in the Russian cohort of CML patients who discontinued TKI therapy. Materials and methods. WS was evaluated in total of 183 CML patients with chronic phase and sustained deep molecular response (DMR). WS was defined as a musculoskeletal pain newly observed after TKI cessation or as a worsening of previously observed symptoms. Results. DMR loss free survival at 36 months was 49% and 43% in prospective and retrospective groups respectively (p=0.96) with mеdian (Me) time of observation 33 months (range 1136). WS was observed in 49 (27%) patients: grade 12 was in 45 (92%) patients, grade 3 in 4 (8%) patients. Me time to WS occurrence was 2 months (range 17), Ме duration of WS was 5 months (range 135). WS was resolved in 14 of 15 patients with molecular relapse after 13 months of TKI re-initiation and was decreased in 1 patient. WS was completely resolved in 31 of 34 patients who continued remained in TFR and decreased in 3 patients. WS was resolved spontaneously or with nonsteroidal anti-inflammatory drugs in 14 (45%) and 17 (55%) patients accordingly. Older age (p0.0001), longer duration of TKI therapy (p0.0001) and presence of locomotion system diseases (p=0.022) were observed in patients with WS. No WS was observed in pregnant patients (р0.001). Survival without DMR loss at 12 months after TKI stop was 66 and 42% in patients with and without WS accordingly (р=0.095). Conclusion. The rate of WS was 27% that is in a good concordance with the data of the other TFR studies. A longer period of TKI exposure, older age and the history of locomotion system diseases were associated with the development of the WS. We found for the first time that WS was not observed in patients with pregnancy. There was no association of WS development and the rate of molecular relapses.


  • Open Access

    Regional hematology service registration system for the Russian Federation

    by I. R. Gerasimova, O. V. Lazareva, Yu. A. Chabaeva, E. S. Maloletkina, S. M. Kylikov, N. N. Tsyba, T. Ts. Garmaeva, V. G. Savchenko

    Introduction. The hematology service registration system describes actual indicators of hematology service infrastructure and target objects of both assigned and affiliated organizations of Russian Federation regions along with its correlations. This system data base makes it possible to collect, save, and analyze information, creating a data storage library about all current existing resources and taking into account concrete, specific conditions of specialized and high-tech hematological medical assistance organizations at the local levels and formed quality and availability optimization proposals.Aim — description and justification of the need to create a unified, complex, available to all users, informational reference system with the possibility of up-to-date maintenance and accounting that allows for the keep and control of the regional characteristics and hematology service indicators of the Russian Federation.General findings. The creation of and development of the hematology service registration system began in 2018, and work on the project continues. Four main phases were selected as the key stages of the hematology service pasportisation: analyses of the current data, verification of information, creation of a user-friendly tool, system updating. Objects to monitor: medical key and related institutions, universities, affiliated organizations, laboratory service. The data working stages: data collection, manual updating, package uploading. The information sources: official websites, data high-tech medical treatment web portal, web portals of the public health authorities, Compulsory Medical Insurance Fund website, The Unified Data Health Care System, license register of the Federal Service for Healthcare Surveillance, data of the Federal State Statistics Service, official documents of Ministry of Public Health. Based on the developed checklists and forms for entering additional information for specialists of the subjects of the Russian Federation, a reference book of the Ministry of Defense (Excel file format) was created. However, in the course of further remote interaction and conducting field events in the regions of the Russian Federation during 2019–2020 new data needs for evaluating hematology services were determined. The increase of additional data inputs and its structure complication became the main reasons for further developing a new platform design concept and data conversion in database framework of the hematology service registration system (Access file format). The current objectives are as follows: authentication of the internal objects identifiers, implementation of the relational database codifier, modification of cartographic display and objects routing. The hematology service registration system contains data both for the key infrastructure nodes of Russian Federation hematology service and correlations within routing of all key system objects. Based on the positive results, the hematology service registration system is planned to be used by experts of specialized medical organizations, regional executive authorities on public health and professional communities, who will be able to accumulate all changes and indicators in dynamics within one system. The expected result is to provide the Ministry of Defense of the Russian Federation regions with methodological and informational support in specialized and high-tech medical care administration.


  • Open Access

    A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy

    by A. G. Turkina, A. N. Petrova, E. Yu. Chelysheva, O. A. Shukhov, O. N. Tsyba, A. K. Golenkov, L. L. Vysotskaia, A. V. Bykova, I. S. Nemchenko, G. A. Gusarova, et al.

    Introduction. The advent of tyrosine kinase inhibitors (TKIs) in clinical practice drastically improved prognosis in patients with chronic myeloid leukaemia (CML). Adverse events of the TKI therapy and its high financial burden warrant the trend to gradually abandon this treatment.Aim. To assess the results of CML patient monitoring after the withdrawal of TKI therapy.Patients and methods. This prospective study included 98 chronic phase CML patients satisfying the criteria: any receiving of TKI therapy for ≥3 years; deep molecular response (DMR, BCR-ABL ≤ 0.01 % IS) during ≥ 2 years. The withdrawal was followed by quantitative BCR-ABL estimation performed monthly for the first 6 months of the survey, bimonthly for 1 year and every 3 months from the second year onwards. Therapy was resumed at a loss of major molecular response (MMR, BCR-ABL ≥ 0.1 % IS).Results. The MMR loss upon the TKI withdrawal was observed in 48 (49 %) patients. Survival without MMR loss was 52 % past 24 months since withdrawal, with a median of 35 months (23–52). The duration of therapy, MR and the MR depth at the time of withdrawal significantly correlated with a conserved post-therapy MMR. Gender, age, a Sokal risk group, type and line of TKI therapy at withdrawal, and imatinib resistance in history were not observed to significantly impact molecular relapse-free remission. MMR was recovered in all 48 patients with TKI therapy resumed in molecular relapse. In 65 % of the patients, adverse therapy events observed during treatment completely resolved by 6 months of post-therapy monitoring. Musculoskeletal pain (withdrawal syndrome, WS) was reported in 42 % patients in the post-therapeutic period, which did not lead to TKI resumption. The WS development correlated with an elder age and longer therapy prior to withdrawal.Conclusion. Molecular relapse-free survival in CML patients with treatment-free remission (TFR) is comparable to other published evidence. Monitoring safety during TFR is attested by the lack of disease progression and MMR recovery upon TKI resumption in all patients.